In vitro cardiomyogenic differentiation of adipose-derived stromal cells using transforming growth factor-beta1.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Transplanting stem cells differentiated towards a cardiac lineage can regenerate cardiac muscle tissues to treat myocardial infarction. In this study, we tested the hypothesis that transforming growth factor-beta1 (TGF-beta1) induces cardiomyogenic differentiation of adipose- derived stromal cells (ADSCs) in vitro. Rat ADSCs were cultured with TGF-beta1 (10 ng ml(-1)) for 2 weeks in vitro. ADSCs cultured without TGF-beta1 served as a control. The mRNA expression of cardiac-specific gene was induced by TGF-beta1, while the control culture did not show cardiac-specific gene expression. Immunocytochemical analyses showed that a small fraction of ADSCs cultured with TGF-beta1 for 2 weeks stained positively for cardiac myosin heavy chain (MHC) and alpha-sarcomeric actin. Flow cytometric analyses showed that the proportion of cells expressing cardiac MHC increased with TGF-beta1. However, no mesenchymal differentiation (e.g., osteogenic and adipogenic differentiation) was detected other than cardiomyogenic differentiation. These results showed that TGF-beta1 induce ADSC cardiomyogenic differentiation in vitro, which could be useful for myocardial infarction stem cell therapy.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.